Heart FailureCHF-AZNCT03390088
Heart Failure Management in Azerbaijan
An observational study of Heart Failure, run by Prof. Dr. Mehdi Zoghi at 1 site in Azerbaijan.
Trial summary
This study is proposed to determined a national database of the etiologies, clinical and the demographic profile, using diagnostic tests and treatment of outpatients with chronic heart failure in Azerbaijan population. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Heart Failure
- How many people
- 0 participants
- Where
- 1 siteAzerbaijan
- Study dates
- 28 Jan 2018to 14 Jan 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: outpatients with chronic heart failure
Who may be able to join
- Patients >18 years olds
- Clinical diagnosis of heart failure
- NYHA class II-IV heart failure
Who cannot join
- Patients <18 years old
- Failure to obtain informed consent
- Pregnant or lactating
- Previous cardiac transplantation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Clinical Profiles and Treatment Management of Chronic Heart Failure in Azerbaijan
This study is proposed to determined a national database of the etiologies, clinical and the demographic profile, using diagnostic tests and treatment of outpatients with chronic heart failure in Azerbaijan population.
Read the detailed description
Chronic heart failure remains the leading cause of hospitalization for those over the age of 65 and expected to increase over the next 25 years with advancing life span. Being a progressive syndrome, CHF decreases the quality of life and place an economic burden on health care system.
Advanced technologies in interventional cardiology, better organization of angiographic laboratories and primary prevention of coronary artery disease as the leading cause of HF, allowed warning its development in CAD patients. But the incidence and prevalence of CHF continue to increase with age as heart failure with preserved ejection fraction predominates in elderly patients. For the moment more than 23 million people over the world suffer from heart failure.
The prevalence of these patients remains very high even in USA - over 5.8 million.However, there is no any database for heart failure patient in Azerbaijan.The purpose of this study is to compose a national database of the etiologies, clinical and demographic characteristics, using diagnostic tests and management of outpatients heart failure in Azerbaijan population.
- Conditions
- Heart Failure
- Keywords
- Heart failure
- Medical subject headings
- Heart Failure
What is being measured
The primary outcome is the main question the study is designed to answer.
Heart failure related hospitalization
Heart failure related hospitalization within 6 months
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jan 2018
- Study start28 Jan 2018
- Primary completion28 Dec 2019 (estimated)
- Study completion14 Jan 2020 (estimated)
Why it stopped: The estimated number of patients could not be recorded in this study
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Prof. Dr. Mehdi Zoghi
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Prof. Dr. Mehdi Zoghi, World Heart Failure Society
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03390088
- Sponsor's protocol ID
- 2018-1
- Acronym
- CHF-AZ
- Status last verified
- Feb 2020
- First submitted
- 26 Dec 2017
- Last updated
- 11 Feb 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Clinical Profiles and Treatment Management of Chronic Heart Failure in Azerbaijan
- ClinicalTrials.gov ID
- NCT03390088
- Acronym / sponsor ID
- CHF-AZ / 2018-1
- Conditions
- Heart Failure
- Keywords
- Heart failure
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: The estimated number of patients could not be recorded in this study
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Prof. Dr. Mehdi ZoghiUniversity, hospital or other
- Study start
- 28 Jan 2018 (actual)
- Primary completion
- 28 Dec 2019 (estimated)
- Study completion
- 14 Jan 2020 (estimated)
- First posted
- 4 Jan 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is proposed to determined a national database of the etiologies, clinical and the demographic profile, using diagnostic tests and treatment of outpatients with chronic heart failure in Azerbaijan population.
Detailed description
Chronic heart failure remains the leading cause of hospitalization for those over the age of 65 and expected to increase over the next 25 years with advancing life span. Being a progressive syndrome, CHF decreases the quality of life and place an economic burden on health care system.
Advanced technologies in interventional cardiology, better organization of angiographic laboratories and primary prevention of coronary artery disease as the leading cause of HF, allowed warning its development in CAD patients. But the incidence and prevalence of CHF continue to increase with age as heart failure with preserved ejection fraction predominates in elderly patients. For the moment more than 23 million people over the world suffer from heart failure.
The prevalence of these patients remains very high even in USA - over 5.8 million.However, there is no any database for heart failure patient in Azerbaijan.The purpose of this study is to compose a national database of the etiologies, clinical and demographic characteristics, using diagnostic tests and management of outpatients heart failure in Azerbaijan population.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- outpatients with chronic heart failure
Key inclusion criteria (3 listed)
- Patients >18 years olds
- Clinical diagnosis of heart failure
- NYHA class II-IV heart failure
Key exclusion criteria (4 listed)
- Patients <18 years old
- Failure to obtain informed consent
- Pregnant or lactating
- Previous cardiac transplantation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Heart failure related hospitalization
Time frame: 6 months
Heart failure related hospitalization within 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2020.
Related trials for Heart Failure
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Active, not recruitingObservational study
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Aortic Valve Stenosis
RecruitingPhase 3
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
Acute Heart Failure
Recruiting
Renal Denervation in Patients With Atrial Fibrillation and Hypertension
Atrial Fibrillation (Paroxysmal), Hypertension
Recruiting
Laser Acupuncture for Fatigue in Hemodialysis Patients
ESRD (End Stage Renal Disease), Dialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure, run by Prof. Dr. Mehdi Zoghi at 1 site in Azerbaijan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 11 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Azerbaijan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Heart failure related hospitalization (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2020.